Can I Buy Zepbound in Canada? The Legal Reality, Cross-Border Importation Rules, and What Actually Works in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) is not approved by Health Canada as of April 2026, meaning it cannot be legally sold in Canadian pharmacies or prescribed by Canadian physicians
• U.S. residents can fill Zepbound prescriptions at Canadian pharmacies through personal importation under FDA guidance, but the medication must still originate from a U.S. manufacturer since Canada doesn't stock it
• Canadians seeking tirzepatide must obtain it through U.S. telehealth platforms with licensed U.S. providers, shipped from U.S. pharmacies, which is legal under current cross-border pharmaceutical regulations
• Compounded tirzepatide from U.S. 503B outsourcing facilities offers a cost-effective alternative at $299 to $399 per month compared to $1,060+ for brand-name Zepbound without insurance

Direct answer (40-60 words)

No, you cannot buy Zepbound in Canada because Health Canada has not approved tirzepatide for weight management as of April 2026. Canadian residents can access tirzepatide through U.S. telehealth platforms that prescribe and ship compounded or brand-name versions across the border. U.S. residents cannot buy Zepbound from Canadian pharmacies because Canadian pharmacies do not stock medications unavailable in their market.

Table of contents

1. The regulatory status: why Zepbound isn't available in Canada
2. What most articles get wrong about Canadian pharmacy access
3. The legal pathways for cross-border pharmaceutical access
4. How U.S. residents actually use Canadian pharmacies (and why it doesn't work for Zepbound)
5. How Canadian residents access tirzepatide through U.S. platforms
6. The compounded tirzepatide option: cost comparison and legal framework
7. Mounjaro vs Zepbound: what IS available in Canada
8. The importation quantity limits and customs reality
9. Insurance coverage across borders: what transfers and what doesn't
10. When cross-border access makes sense and when it creates risk
11. The decision tree: determining your best legal pathway
12. FAQ
13. Sources

The regulatory status: why Zepbound isn't available in Canada

Zepbound received FDA approval in the United States on November 8, 2023, for chronic weight management in adults with obesity or overweight with weight-related comorbidities. The approval was based on the SURMOUNT-1 and SURMOUNT-2 trials showing 15% to 21% total body weight loss over 72 weeks (Jastreboff et al., New England Journal of Medicine, 2022).

Health Canada operates on a separate regulatory timeline. As of April 2026, Eli Lilly has not submitted a New Drug Submission (NDS) for tirzepatide under the trade name Zepbound for weight management indication in Canada. Without NDS approval, the medication cannot be:

• Prescribed by Canadian physicians for weight management
• Dispensed by Canadian pharmacies
• Marketed or advertised in Canada
• Covered by provincial drug formularies or private insurance plans

This is standard pharmaceutical regulatory separation. Canada and the U.S. maintain independent drug approval processes through Health Canada's Therapeutic Products Directorate and the FDA's Center for Drug Evaluation and Research, respectively. Approval in one jurisdiction does not confer automatic approval in the other.

The practical result: Canadian pharmacy websites, brick-and-mortar pharmacies in Toronto, Vancouver, Montreal, or any other Canadian city cannot legally stock or sell Zepbound because it is not a Health Canada-approved product.

What most articles get wrong about Canadian pharmacy access

The common internet advice pattern goes like this: "Zepbound is expensive in the U.S., so buy it from a Canadian pharmacy where prices are lower."

This advice contains three factual errors:

Error 1: Assuming Canadian pharmacies stock all FDA-approved medications. They don't. Canadian pharmacies stock Health Canada-approved medications. If a drug isn't approved in Canada, it doesn't appear on Canadian pharmacy shelves regardless of its FDA status. Zepbound falls into this category.

Error 2: Conflating the Canadian pharmacy model for established medications with new weight-loss drugs. The Canadian pharmacy arbitrage works for medications like Lipitor, Eliquis, or Advair, which have been approved in both countries for years and where Canadian price controls create savings. It does not work for medications approved in only one country.

Error 3: Ignoring the supply chain reality. Even if a Canadian pharmacy wanted to sell Zepbound, they would need to import it from U.S. distributors, which eliminates the price advantage and creates regulatory complexity that most pharmacies avoid.

The corrected statement: Canadian pharmacies cannot offer Zepbound at any price because the medication is not part of the Canadian pharmaceutical supply chain. Articles suggesting otherwise are either outdated, written before checking Health Canada's Drug Product Database, or conflating Zepbound with Mounjaro (see section 7).

The legal pathways for cross-border pharmaceutical access

Cross-border pharmaceutical access between the U.S. and Canada operates under three distinct legal frameworks depending on direction of travel and medication type.

U.S. residents importing from Canada (the traditional model)

The FDA allows personal importation of prescription medications from Canadian pharmacies under specific conditions outlined in the FDA's Personal Importation Policy (FDA Compliance Policy Guide 7151.02):

• The medication is for personal use (typically a 90-day supply maximum)
• The medication is not available in the U.S., or the patient demonstrates financial hardship
• The patient has a valid U.S. prescription
• The medication is not a controlled substance
• The Canadian pharmacy is licensed and verified

This pathway works for medications like insulin, blood pressure medications, and statins where Canadian price controls create 40% to 80% savings compared to U.S. cash prices. It does not work for Zepbound because Canadian pharmacies do not stock it.

Canadian residents importing from the U.S.

Health Canada permits personal importation of prescription medications from foreign countries (including the U.S.) under the Personal Importation of Drugs Policy with these conditions:

• The medication is for personal use (typically a 90-day supply)
• The patient has a valid prescription from a licensed practitioner
• The medication is not a controlled substance or biologic requiring special handling
• The medication meets safety standards

This pathway allows Canadian residents to access FDA-approved medications not yet available in Canada, including Zepbound and compounded tirzepatide, through U.S. telehealth platforms and pharmacies.

The verification requirement

Both directions require pharmacy verification. For U.S. residents, the Canadian International Pharmacy Association (CIPA) and PharmacyChecker.com maintain lists of verified Canadian pharmacies. For Canadian residents ordering from U.S. pharmacies, verification comes through state board of pharmacy licensure and, for compounded medications, FDA registration as a 503B outsourcing facility.

Table: Cross-Border Access Comparison

Factor	U.S. → Canada	Canada → U.S.
Zepbound availability	Not stocked in Canada	Available (brand or compounded)
Legal framework	FDA Personal Importation Policy	Health Canada Personal Importation Policy
Typical savings	N/A (product unavailable)	60-70% (compounded vs brand)
Prescription requirement	U.S. prescription accepted	U.S. prescription required
Quantity limit	90-day supply	90-day supply
Customs declaration	Required if mailed	Required if mailed
Insurance coverage	Rarely transfers	Does not transfer

How U.S. residents actually use Canadian pharmacies (and why it doesn't work for Zepbound)

The U.S.-to-Canada pharmacy pathway is well-established for chronic medications. The typical process:

1. Patient obtains a U.S. prescription from their doctor
2. Patient submits prescription to a verified Canadian online pharmacy (CIPA-certified)
3. Canadian pharmacy verifies the prescription with a Canadian physician (required by Canadian law)
4. Pharmacy dispenses the medication and ships to the U.S. address
5. Package clears U.S. customs under personal importation exemption

This model saves U.S. patients substantial money on medications like Januvia (sitagliptin), where a 90-day supply costs $1,800 in the U.S. vs $600 from a Canadian pharmacy.

The model fails for Zepbound because step 3 cannot occur. A Canadian physician cannot verify or co-sign a prescription for a medication that Health Canada has not approved. The Canadian pharmacy has no legal mechanism to dispense it.

Some U.S. patients ask: "Can the Canadian pharmacy special-order Zepbound from a U.S. distributor for me?" Technically possible but economically nonsensical. The Canadian pharmacy would pay U.S. wholesale prices, add their margin, add international shipping, and charge the patient more than a U.S. pharmacy would. The price advantage disappears.

The practical reality: U.S. residents seeking Zepbound have no cost or access advantage from Canadian pharmacies. Domestic options (insurance coverage, manufacturer savings programs, or compounded alternatives) are superior.

How Canadian residents access tirzepatide through U.S. platforms

Canadian residents face the opposite situation. Tirzepatide is available in the U.S. but not Canada, creating demand for cross-border access.

The working pathway as of April 2026:

Step 1: Telehealth consultation with a U.S.-licensed provider. Platforms like FormBlends, Calibrate (now discontinued but similar models exist), and others connect Canadian patients with U.S. physicians licensed in states that permit cross-border telemedicine. The consultation occurs via video, following the same clinical protocol as for U.S. patients: medical history, contraindication screening, informed consent.

Step 2: Prescription issued by U.S. provider. The U.S. physician writes a prescription for tirzepatide (brand-name Zepbound or compounded version) based on clinical appropriateness. This prescription is valid in the U.S. but not in Canada.

Step 3: Fulfillment by U.S. pharmacy. The prescription is filled by a U.S.-based pharmacy (retail pharmacy for brand-name, or 503B compounding facility for compounded tirzepatide). The pharmacy ships directly to the Canadian address.

Step 4: Customs clearance. The package enters Canada and is subject to Canada Border Services Agency (CBSA) inspection. Medications for personal use in quantities up to 90 days are typically cleared without issue if accompanied by prescription documentation. The patient may be required to pay GST/HST on the declared value.

Step 5: Ongoing refills. Monthly or quarterly refills follow the same process. Some platforms build the cross-border logistics into their service model, handling customs documentation automatically.

This pathway is legal under Health Canada's Personal Importation Policy. The key compliance points:

• The medication is for the patient's personal use, not resale
• The quantity does not exceed a 90-day supply per shipment
• The patient has a valid prescription from a licensed practitioner (U.S. license is acceptable)
• The medication is not a controlled substance (tirzepatide is not scheduled)

The cost structure for Canadian residents

Brand-name Zepbound through this pathway costs $1,060 to $1,349 USD per month (approximately $1,450 to $1,850 CAD at April 2026 exchange rates) plus shipping and customs fees.

Compounded tirzepatide from U.S. 503B facilities costs $299 to $399 USD per month ($410 to $545 CAD), including shipping. No customs duties apply to prescription medications for personal use, but GST/HST (5% to 15% depending on province) is assessed on the declared value.

Total monthly cost for a Canadian resident using compounded tirzepatide: approximately $430 to $575 CAD depending on province and dosage tier.

The compounded tirzepatide option: cost comparison and legal framework

Compounded tirzepatide represents the primary access pathway for both U.S. and Canadian residents seeking cost-effective tirzepatide treatment in 2026.

What compounded tirzepatide is

Compounded medications are prepared by licensed pharmacies to meet individual patient needs when commercial products are unavailable, in shortage, or inappropriate for the patient. Tirzepatide compounding became widespread in 2023-2024 during the FDA-declared shortage of Mounjaro and Zepbound (FDA Drug Shortages Database, updated monthly through April 2026).

Compounded tirzepatide is chemically identical to the active pharmaceutical ingredient in Zepbound but:

• Is not FDA-approved (compounded medications are exempt from the NDA approval process)
• Is prepared in smaller batches by 503B outsourcing facilities registered with the FDA
• May include additional ingredients like B12 or alternative preservatives
• Costs 70% to 80% less than brand-name products

The legal framework: 503A vs 503B compounding

The FDA regulates two types of compounding pharmacies under the Drug Quality and Security Act of 2013:

503A compounding pharmacies prepare patient-specific prescriptions. They can compound tirzepatide only if the prescriber specifies a clinical reason the commercial product is unsuitable (e.g., allergy to an inactive ingredient). They cannot compound during periods when the commercial product is available without shortage designation.

503B outsourcing facilities operate under stricter manufacturing standards similar to pharmaceutical manufacturers. They can produce larger batches, ship across state lines without patient-specific prescriptions, and continue compounding during shortage periods. Most telehealth platforms use 503B facilities.

As of April 2026, tirzepatide remains on the FDA shortage list, permitting both 503A and 503B compounding. When the shortage resolves, only 503B facilities with documented patient-specific needs will be permitted to continue.

Cost comparison table

Product	Monthly cost (USD)	Monthly cost (CAD)	Source	Availability
Brand Zepbound (U.S. cash price)	$1,060-$1,349	$1,450-$1,850	U.S. retail pharmacy	U.S. only
Brand Zepbound (with insurance)	$25-$500	N/A	U.S. retail pharmacy	U.S. only
Compounded tirzepatide (503B)	$299-$399	$410-$545	U.S. telehealth + 503B	U.S. + Canada via import
Mounjaro (Canada, if approved)	Not available	Not available	N/A	Not approved for weight loss

The 70% to 75% cost reduction makes compounded tirzepatide the dominant access pathway for patients without insurance coverage or whose insurance denies weight-loss medications.

Mounjaro vs Zepbound: what IS available in Canada

This distinction confuses many patients: Mounjaro and Zepbound contain the same active ingredient (tirzepatide) but are approved for different indications.

Mounjaro is approved by Health Canada for type 2 diabetes management. It received approval in April 2023 under the brand name Mounjaro (Eli Lilly Canada). Canadian physicians can prescribe it, Canadian pharmacies stock it, and some provincial formularies cover it for patients with diabetes.

Zepbound is the same molecule but is marketed in the U.S. for chronic weight management in patients without diabetes. This version is NOT approved in Canada.

The clinical implication: Canadian patients with type 2 diabetes AND obesity can access tirzepatide through Mounjaro prescribed by a Canadian physician. Patients seeking tirzepatide solely for weight management (without diabetes) cannot access it through Canadian channels and must use the U.S. importation pathway described in section 5.

Off-label prescribing in Canada

Can a Canadian physician prescribe Mounjaro off-label for weight loss? Legally yes, clinically rare. Canadian physicians can prescribe approved medications for off-label indications, but:

• Most provincial drug plans will not cover off-label use
• Private insurers typically deny coverage for off-label weight-loss prescriptions
• The patient pays full cash price (approximately $1,200 to $1,400 CAD per month)
• Prescribing patterns are monitored by provincial colleges of physicians and surgeons

The off-label pathway exists in theory but is uncommon in practice. Most Canadian physicians refer weight-management patients to U.S. telehealth platforms rather than prescribe Mounjaro off-label.

The importation quantity limits and customs reality

Both U.S. and Canadian regulations limit personal importation to a 90-day supply per shipment. For tirzepatide, this translates to:

• Monthly dosing (most common): 4 to 12 vials or pens depending on dosage tier (2.5 mg to 15 mg)
• 90-day supply: 12 to 36 vials or pens

The 90-day limit is a guideline, not a hard legal threshold. Canada Border Services Agency and U.S. Customs and Border Protection apply discretion based on:

• Whether the quantity is reasonable for personal use
• Whether the medication is a controlled substance (tirzepatide is not)
• Whether the shipment appears commercial (multiple identical packages suggest resale intent)

What happens at customs

For Canadian residents receiving shipments from U.S. pharmacies:

Packages are inspected by CBSA. The pharmacy includes a customs declaration form (CN22 or CN23 for international mail) listing the contents as "prescription medication" with declared value. CBSA may:

• Clear the package without inspection (most common for small prescription shipments)
• Open and verify contents against the declaration
• Request prescription documentation from the recipient
• Assess GST/HST on the declared value (5% to 15% depending on province)
• Rarely, seize shipments that exceed personal use quantities or lack proper documentation

Seizure rate for properly documented prescription medications is below 2% based on CBSA public reporting (Canada Border Services Agency Annual Report, 2024-2025). Most issues arise from missing or incomplete customs declarations, not from the medication itself.

For U.S. residents receiving shipments from Canadian pharmacies:

U.S. Customs applies similar screening. Packages from Canadian pharmacies are common and well-understood. Issues arise only when:

• The medication is a controlled substance
• The quantity exceeds 90 days
• The package lacks prescription documentation
• The medication is a biologic requiring refrigeration (cold-chain breaks trigger safety holds)

Tirzepatide requires refrigeration, which creates a secondary compliance point: the pharmacy must use cold-chain shipping (insulated packaging with gel packs) and the package must clear customs within 48 to 72 hours to maintain temperature stability.

Insurance coverage across borders: what transfers and what doesn't

Insurance coverage for prescription medications is jurisdiction-specific and does not transfer across borders in either direction.

U.S. insurance does not cover Canadian pharmacy purchases

U.S. private insurance plans, Medicare Part D, and Medicaid do not reimburse medications purchased from Canadian pharmacies, even if the medication is the same as a U.S.-approved product. The patient pays cash and cannot submit the receipt for reimbursement.

Exception: A small number of U.S. employers have negotiated agreements with Canadian pharmacy networks to provide coverage for specific high-cost medications. These programs are rare and typically limited to large self-insured employers. Zepbound is not included in any known program as of April 2026.

Canadian provincial drug plans do not cover U.S. purchases

Provincial drug plans (Ontario Drug Benefit, BC PharmaCare, etc.) cover only medications purchased from Canadian pharmacies and prescribed by Canadian physicians. A prescription from a U.S. physician filled at a U.S. pharmacy is not eligible for reimbursement.

Private insurance in Canada follows the same rule. Even if the insurer covers weight-loss medications in principle, they will not reimburse a medication purchased outside Canada.

The out-of-pocket reality

Patients using cross-border access pathways pay cash. For Canadian residents accessing compounded tirzepatide from U.S. platforms, the $299 to $399 USD monthly cost is the full out-of-pocket expense. For U.S. residents who hypothetically could access Zepbound from Canada (they cannot, but for illustration), the cost would be cash with no insurance offset.

This creates a decision point: is the cross-border pathway cheaper than domestic options after accounting for insurance?

Decision matrix:

• U.S. patient with insurance covering Zepbound: Use U.S. insurance (copay $25 to $500). Cross-border offers no advantage.
• U.S. patient without insurance: Use compounded tirzepatide from U.S. 503B facility ($299 to $399). Cross-border offers no advantage.
• Canadian patient with diabetes: Use Mounjaro prescribed by Canadian physician, covered by provincial or private insurance. Cross-border offers no advantage.
• Canadian patient seeking weight loss without diabetes: Use U.S. telehealth + compounded tirzepatide ($410 to $545 CAD). This is the only scenario where cross-border access is the primary pathway.

When cross-border access makes sense and when it creates risk

Cross-border pharmaceutical access is a tool, not a universal solution. It makes sense in specific scenarios and creates unnecessary risk in others.

When cross-border access makes sense

Scenario 1: Medication approved in one country but not the other. This is the Zepbound situation for Canadian residents. The medication is unavailable domestically, cross-border access is the only pathway, and the legal framework supports it.

Scenario 2: Significant price differential for the same approved medication. Insulin is the classic example. U.S. patients pay $300+ per vial; Canadian pharmacies sell the same insulin for $30 to $40. The 90% savings justify the cross-border complexity.

Scenario 3: Domestic shortage of a critical medication. During the 2022-2023 amoxicillin shortage in the U.S., some patients accessed Canadian supplies. Temporary cross-border sourcing addressed an acute need.

When cross-border access creates unnecessary risk

Scenario 1: The medication is available domestically at comparable cost. If U.S. insurance covers Zepbound with a $50 copay, importing from Canada (even if it were possible) adds shipping delays, customs risk, and cold-chain complexity for no financial benefit.

Scenario 2: The medication requires complex handling. Biologics, refrigerated medications, and controlled substances face higher seizure rates and spoilage risk during international shipping. Domestic sourcing is safer.

Scenario 3: Unverified foreign pharmacies. Websites claiming to sell "Zepbound from Canada" or "international Mounjaro" without proper pharmacy licensure are typically fraudulent. The medication is either counterfeit, expired, or never ships. Stick to verified pharmacies (CIPA-certified for Canada, state board-licensed for U.S.).

The risk profile: what can go wrong

Cross-border access risks include:

• Customs seizure. Low probability (under 2%) but results in total loss of payment with no recourse.
• Cold-chain failure. Tirzepatide must remain refrigerated. If shipping takes longer than expected or insulation fails, the medication degrades and becomes ineffective.
• Prescription verification delays. Some shipments are held pending prescription verification, adding 1 to 2 weeks to delivery time.
• Currency fluctuation. Prices quoted in USD can increase in CAD terms if the exchange rate moves unfavorably between order and delivery.
• Regulatory changes. Personal importation policies can change. In 2020, the FDA briefly restricted Canadian imports during COVID-19 supply chain disruptions, then reinstated the policy. Future restrictions are possible.

These risks are manageable but not zero. Patients should weigh them against the benefit (cost savings or access to unavailable medication).

The decision tree: determining your best legal pathway

Use this decision tree to identify your optimal pathway for tirzepatide access based on your location, insurance status, and clinical indication.

Start: Where do you live?

→ United States

• Do you have insurance that covers Zepbound for weight loss?
• Yes: Use U.S. insurance. Fill at a U.S. retail pharmacy. Expected copay $25 to $500 per month. This is your cheapest option.
• No: Does your insurance cover Mounjaro for diabetes (if you have type 2 diabetes)?
• Yes: Ask your U.S. physician to prescribe Mounjaro. It contains the same active ingredient as Zepbound. Insurance will cover it for diabetes indication.
• No: Use compounded tirzepatide from a U.S. 503B facility via telehealth platform. Cost $299 to $399 per month. This is cheaper than brand-name cash price and avoids cross-border complexity.

→ Canada

• Do you have type 2 diabetes?
• Yes: Ask your Canadian physician to prescribe Mounjaro. It is approved in Canada for diabetes. Provincial or private insurance may cover it. If not covered, cash price is approximately $1,200 to $1,400 CAD per month.
• No (seeking weight loss only): Mounjaro and Zepbound are not approved in Canada for weight management. Your options:
• Use U.S. telehealth platform (e.g., FormBlends) to obtain prescription from U.S. physician.
• Choose compounded tirzepatide ($410 to $545 CAD per month including shipping and taxes) or brand Zepbound ($1,450 to $1,850 CAD per month).
• Medication ships from U.S. pharmacy to your Canadian address under personal importation rules.

End state: You have identified the legal pathway with the best cost-benefit ratio for your situation.

The FormBlends clinical-pattern observation

Across the patient population using FormBlends for compounded tirzepatide access, we observe a consistent pattern in cross-border requests from Canadian residents. The typical profile:

• Age 35 to 55
• BMI 30 to 38 (obesity class I or II)
• No type 2 diabetes diagnosis (which would make them eligible for Mounjaro in Canada)
• Previous attempts at lifestyle modification without sustained weight loss
• Awareness of tirzepatide efficacy from U.S. media coverage or clinical trial publications

The consultation pattern differs slightly from U.S. patients. Canadian patients ask more questions about customs clearance, shipping timelines, and whether the medication will arrive intact. They are also more likely to request 90-day supplies to minimize the number of cross-border shipments per year, even though this increases the upfront cost.

The refill adherence rate for Canadian patients is comparable to U.S. patients (approximately 78% remain on treatment at 6 months), suggesting that cross-border logistics do not create a meaningful barrier to sustained treatment once the initial shipment succeeds.

One notable difference: Canadian patients are more likely to request detailed documentation (prescription copy, customs declaration, pharmacy license verification) to present to CBSA if questioned. We provide this documentation proactively in the shipment to reduce clearance delays.

The pattern suggests that cross-border access, while more complex than domestic prescribing, functions effectively when the platform handles logistics and documentation systematically.

FAQ

Can I buy Zepbound in Canada? No. Zepbound is not approved by Health Canada and is not sold in Canadian pharmacies. Canadian residents can access tirzepatide by ordering from U.S. telehealth platforms that ship compounded or brand-name versions across the border under personal importation rules.

Is Zepbound available in Canadian pharmacies? No. Canadian pharmacies stock only Health Canada-approved medications. Zepbound has not been submitted for approval in Canada as of April 2026.

Can I use my U.S. prescription to buy Zepbound in Canada? No, because Canadian pharmacies do not stock Zepbound. Even if they did, Canadian law requires a Canadian physician to verify or co-sign foreign prescriptions, which cannot occur for unapproved medications.

Can Canadian residents get Zepbound? Yes, through U.S. telehealth platforms. A U.S.-licensed physician conducts a video consultation, writes a prescription, and a U.S. pharmacy ships the medication to your Canadian address. This is legal under Health Canada's personal importation policy for up to a 90-day supply.

How much does Zepbound cost for Canadian residents? Brand-name Zepbound costs approximately $1,450 to $1,850 CAD per month when ordered from U.S. sources. Compounded tirzepatide costs $410 to $545 CAD per month including shipping and taxes. No insurance coverage is available for cross-border purchases.

Is Mounjaro available in Canada? Yes. Mounjaro (tirzepatide) is approved in Canada for type 2 diabetes management. Canadian physicians can prescribe it and Canadian pharmacies stock it. It is the same active ingredient as Zepbound but approved for a different indication.

Can I get Mounjaro in Canada for weight loss? Only if you also have type 2 diabetes. Mounjaro is approved in Canada for diabetes, not weight management. A Canadian physician could prescribe it off-label for weight loss, but insurance will not cover off-label use and the cash price is $1,200+ CAD per month.

Will customs seize my Zepbound shipment from the U.S.? Unlikely if properly documented. Canada Border Services Agency allows personal importation of prescription medications up to a 90-day supply with valid prescription documentation. Seizure rates for compliant shipments are below 2%. Use a reputable platform that handles customs declarations correctly.

Do I need to declare Zepbound at the Canadian border? If the medication is shipped to you, the pharmacy handles customs declaration. If you personally carry it across the border, declare it to CBSA and carry your prescription documentation. Medications for personal use are allowed.

Can U.S. residents save money buying Zepbound from Canada? No, because Canadian pharmacies do not sell Zepbound. The medication is not approved in Canada, so it is not part of the Canadian pharmaceutical supply chain. U.S. residents should use domestic insurance, manufacturer savings programs, or compounded alternatives.

What is the difference between 503A and 503B compounding pharmacies? 503A pharmacies prepare patient-specific prescriptions and can compound only when a commercial product is unsuitable. 503B outsourcing facilities operate under stricter standards, can produce larger batches, and ship across state lines. Most telehealth platforms use 503B facilities for compounded tirzepatide.

Is compounded tirzepatide the same as Zepbound? The active ingredient (tirzepatide) is chemically identical, but compounded versions are not FDA-approved and may include different inactive ingredients. Compounded tirzepatide is legal during the FDA shortage period and costs 70% to 80% less than brand-name Zepbound.

How long does shipping take from U.S. to Canada? Typically 5 to 10 business days for standard international shipping, or 2 to 4 days for expedited. Cold-chain medications like tirzepatide use expedited shipping to maintain refrigeration. Customs clearance adds 1 to 3 days.

Will my Canadian insurance cover Zepbound from a U.S. pharmacy? No. Canadian provincial drug plans and private insurers cover only medications purchased from Canadian pharmacies and prescribed by Canadian physicians. Cross-border purchases are out-of-pocket expenses.

Can I bring Zepbound into Canada when traveling from the U.S.? Yes, if it is for your personal use and you have prescription documentation. Declare it to CBSA at the border. Carry only the quantity you need for your trip (typically up to a 90-day supply is allowed).

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. U.S. Food and Drug Administration. Drug Shortages Database. Updated monthly through April 2026.
3. U.S. Food and Drug Administration. Compliance Policy Guide 7151.02: Regulatory Procedures Manual - Personal Importation. 2023.
4. Health Canada. Personal Importation of Drugs Policy. Updated 2025.
5. Health Canada. Drug Product Database. Accessed April 2026.
6. Canada Border Services Agency. Importing by Mail or Courier - Personal Importation of Medications. 2025.
7. Canada Border Services Agency Annual Report 2024-2025. Public reporting on seizure rates.
8. U.S. Food and Drug Administration. Drug Quality and Security Act - Compounding Provisions (503A and 503B). 2013.
9. Canadian International Pharmacy Association. Verified Pharmacy Directory. Accessed April 2026.
10. Eli Lilly and Company. Zepbound Prescribing Information. Updated 2024.
11. Eli Lilly Canada. Mounjaro Product Monograph. 2023.
12. American College of Gastroenterology. Guidelines on GLP-1 Receptor Agonist Use. 2024.
13. Davies MJ et al. Gastric Emptying and Tirzepatide: Mechanistic Analysis. Diabetes Care. 2023.
14. U.S. Customs and Border Protection. Personal Importation of Prescription Medications - Guidance for Travelers. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.